Abstract
Neuropathy caused by chemotherapy is a common and debilitating side-effect of cancer treatment. With 30% of patients experiencing chronic neuropathy and with no good evidence-based treatments; early detection triggering chemotherapy regime modification remains the best option for prevention. Early detection is challenging because of a lack of diagnostic tools with sufficient longitudinal temporal precision and convenience for patient/clinical adoption. To tackle this problem, we developed SenseCheQ; enabling self-administered autonomous sensory testing which can be used by patients at home. We present the instrumental engineering approach taken to address the challenge, including haptic self-calibration combined with skin thermal-clamping protocols, and demonstrate robustly reliable performance in the face of environmental and user-related variance in home settings. We present prospective case studies of people having chemotherapy treatment for cancer, conducting regular unsupervised quantitative sensory testing to monitor their nerve function at home. These proof-of-principle studies show SenseCheQ can detect sub-clinical changes in nerve function, matching patient reported outcomes and lab-based sensory testing. This highlights SenseCheQ’s promise as a scalable biomarker platform for neuropathy-detection and therapeutic development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The SenseCheQ research project was funded as part of the Advanced Pain Discovery Platform by a consortium made up of UKRI MRC, Arthritis UK, and Eli Lilly all coordinated by the MRC [MR/W027925/1] as well as by UKRI EPSRC [UKRI1437]. BT was also supported by an APDP grant as part of the Partnership for Assessment and Investigation of Neuropathic Pain: Studies Tracking Outcomes, Risks and Mechanisms (PAINSTORM) consortium [MR/W002388/1].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the University of Bristol Research Ethics Committee (project ID:9994) and from Health Research Authority and the Health and Care Research Wales (IRAS project ID: 327541)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in this manuscript is available via Open Science Framework (https://doi.org/10.17605/OSF.IO/4GD2H).
